Patents by Inventor Vaughn P. Miller

Vaughn P. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of fluorescein aryl ethers in high throughput cytochrome P450 inhibition assays
    Patent number: 6420131
    Abstract: Novel fluorescent substrates of human cytochrome P450 enzymes are provided. Also provided are methods for their manufacture and use. These substrates are useful in assessing cytochrome P450 enzyme activity and in selecting compounds which inhibit cytochrome P450 enzyme activity and, in particular, for identifying potential adverse drug interactions which are mediated by inhibition of cytochrome P450 enzyme activity.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: July 16, 2002
    Assignee: Gentest Corporation
    Inventors: Vaughn P. Miller, David Streser, Charles L. Crespi
  • Coumarin-based CYP3A fluorescent assay reagents
    Patent number: 6207404
    Abstract: Novel fluorescent substrates of human cytochrome P450 enzymes are provided. Also provided are methods for their manufacture and use. These substrates are useful in assessing cytochrome P450 enzyme activity and in selecting compounds which inhibit cytochrome P450 enzyme activity and, in particular, for identifying potential adverse drug interactions which are mediated by inhibition of cytochrome P450 enzyme activity. The compounds are particularly useful for assessing cytochrome P450 CYP3A enzyme activity.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: March 27, 2001
    Assignee: Gentest Corporation
    Inventors: Vaughn P. Miller, Charles L. Crespi
  • CYP2D fluorescent assay reagents
    Patent number: 6130342
    Abstract: Novel fluorescent substrates of the human P450 enzyme CYP2D6 are provided. Also provided are methods for their manufacture and use. These substrates are useful in assessing CYP2D6 enzyme activity and in selecting compounds which inhibit CYP2D6 enzyme activity and, in particular, for identifying potential adverse drug interactions which are mediated by inhibition of CYP2D6 enzyme activity.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: October 10, 2000
    Assignee: Gentest Corporation
    Inventors: Vaughn P. Miller, Charles L. Crespi